Lupus & antiphospholipid syndrome
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus
Authors' conclusion
LC infiltration in the lymph nodes of patients with SLE is relatively common and should be carefully evaluated to prevent misdiagnosis.
Study context
- Population
- Newly diagnosed, treatment-naïve patients with SLE, with and without lymphadenopathy
- Participants
- 59 vs 81
- Comparison
- SLE with lymphadenopathy vs SLE without lymphadenopathy (LAP)
- SLE-LAPn = 59
- SLE without LAPn = 81reference
- Outcome
- Clinical features, SLE-LAP vs controls
Main finding
As reported in the abstract
- SLE-LAP
- Fever 64.4% vs 35.8%; P < 0.001
- SLE-LAP
- Anaemia 71.2% vs 42.0%; P < 0.001
- SLE-LAP
- Serous effusion 27.1% vs 11.1%; P = 0.015
- SLE-LAP
- Myositis 10.2% vs 1.2%; P = 0.045
- SLE-LAP
- Elevated CRP 44.1% vs 22.2%; P = 0.006
Observational data: associations, not effects.
Further findings
Fever
P < 0.001
Anaemia
P < 0.001
Serous effusion
P = 0.015
Myositis
P = 0.045
Elevated CRP
P = 0.006
Autoantibodies, more frequent in the LAP group
- Anti-Smith
- 37.3% vs 16.0%, p=0.004
- aCL IgG
- 27.1% vs 11.1%, p=0.015
- aCL IgM
- 42.4% vs 9.9%, p<0.001
- aCL IgA
- 8.5% vs 0.0%, p=0.027
Distribution of Langerhans cells (LCs) on immunohistochemistry
- Scattered
- 58.6%
- Focal
- 41.4%
Presentation of patients with LC infiltration
- Fever
- 72.4%
- Anaemia
- 64.3%
- Skin rashes
- 62.1%
- Arthritis
- 62.1%
Clinical manifestations, LC-positive vs LC-negative
- No significant differences in clinical manifestations between LC-positive and LC-negative patients
Original publication
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus. Lupus Sci Med. Published 14 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →